JP5829217B2 - 高浸透性テルビナフィン製剤 - Google Patents

高浸透性テルビナフィン製剤 Download PDF

Info

Publication number
JP5829217B2
JP5829217B2 JP2012546222A JP2012546222A JP5829217B2 JP 5829217 B2 JP5829217 B2 JP 5829217B2 JP 2012546222 A JP2012546222 A JP 2012546222A JP 2012546222 A JP2012546222 A JP 2012546222A JP 5829217 B2 JP5829217 B2 JP 5829217B2
Authority
JP
Japan
Prior art keywords
formulation
penetration
terbinafine
shows
results
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2012546222A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013515742A5 (enExample
JP2013515742A (ja
Inventor
セルベト ブユクティムキン
セルベト ブユクティムキン
ナディア ブユクティムキン
ナディア ブユクティムキン
ジャガト シン
ジャガト シン
ジョン エム． ニューサム
ジョン エム． ニューサム
ドミニク キング−スミス
ドミニク キング−スミス
エドワード キサク
エドワード キサク
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nuvo Research Inc
Original Assignee
Nuvo Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nuvo Research Inc filed Critical Nuvo Research Inc
Publication of JP2013515742A publication Critical patent/JP2013515742A/ja
Publication of JP2013515742A5 publication Critical patent/JP2013515742A5/ja
Application granted granted Critical
Publication of JP5829217B2 publication Critical patent/JP5829217B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A61K9/0017—Non-human animal skin, e.g. pour-on, spot-on
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
JP2012546222A 2009-12-23 2010-12-22 高浸透性テルビナフィン製剤 Expired - Fee Related JP5829217B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US28996209P 2009-12-23 2009-12-23
US28996709P 2009-12-23 2009-12-23
US61/289,962 2009-12-23
US61/289,967 2009-12-23
PCT/US2010/061940 WO2011079234A2 (en) 2009-12-23 2010-12-22 Highly permeating terbinafine formulation

Publications (3)

Publication Number Publication Date
JP2013515742A JP2013515742A (ja) 2013-05-09
JP2013515742A5 JP2013515742A5 (enExample) 2014-02-13
JP5829217B2 true JP5829217B2 (ja) 2015-12-09

Family

ID=43770418

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012546222A Expired - Fee Related JP5829217B2 (ja) 2009-12-23 2010-12-22 高浸透性テルビナフィン製剤

Country Status (7)

Country Link
US (1) US9084754B2 (enExample)
EP (1) EP2544659A2 (enExample)
JP (1) JP5829217B2 (enExample)
CN (1) CN102770123A (enExample)
AU (1) AU2010336441B2 (enExample)
CA (1) CA2785643A1 (enExample)
WO (1) WO2011079234A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2535827T3 (es) * 2011-02-11 2015-05-18 Moberg Pharma Ab Nueva composición antifúngica
CN104105472A (zh) 2011-12-20 2014-10-15 维奥姆生物科学有限公司 用于治疗真菌感染的局部油组合物
EP2664327A1 (en) * 2012-05-14 2013-11-20 Almirall S.A. Topical pharmaceutical compositions comprising terbinafide and urea
NL2009669C2 (en) * 2012-10-19 2014-04-23 Dutch Renewable Energy B V Enhanced nail penetrating composition.
US9144553B2 (en) 2012-12-21 2015-09-29 Teikoku Pharma Usa, Inc. Compositions and methods for transdermal delivery of hormones and other medicinal agents
US8697753B1 (en) 2013-02-07 2014-04-15 Polichem Sa Method of treating onychomycosis
EP2952208A1 (en) * 2014-06-04 2015-12-09 Universidade de Santiago de Compostela Hydroalcoholic system for nail treatment
HRP20211477T8 (hr) 2014-10-21 2022-03-04 Hexima Limited Postupak liječenja gljivičnih infekcija
KR101690765B1 (ko) * 2015-04-17 2016-12-28 동아제약 주식회사 항진균성 활성물질을 포함하는 경피 제제
GB201511799D0 (en) * 2015-07-06 2015-08-19 Blueberry Therapeutics Ltd Composition and methods of treatment
US9744156B2 (en) 2015-08-17 2017-08-29 Arno Therapeutics, Inc. Methods and compositions for enhanced transungual delivery of AR-12
EP3359133B1 (en) * 2015-10-07 2024-05-01 Exodos Life Sciences LP Topical antifungal compositions
GB201605127D0 (en) * 2016-03-25 2016-05-11 Blueberry Therapeutics Ltd Composition and methods of treatment
WO2017216722A2 (en) * 2016-06-13 2017-12-21 Vyome Biosciences Pvt. Ltd. Synergistic antifungal compositions and methods thereof
JP2019521993A (ja) * 2016-06-13 2019-08-08 ビオーム セラピューティクス リミテッド 相乗的な抗真菌組成物及びその方法
SG10202105118WA (en) 2016-11-28 2021-06-29 Cellix Bio Private Ltd Compositions and methods for the treatment of fungal infections
WO2019214838A1 (en) * 2018-05-09 2019-11-14 Eviderm Institute Ab Use of an alcohol-containing composition for improving the skin barrier function
EP3802502A4 (en) * 2018-06-04 2022-03-30 Zenvision Pharma LLP ANTIFUNGAL CUTICLE OIL COMPOSITION
US20220354783A1 (en) 2018-08-01 2022-11-10 Edix-O Sarl Injectable prolonged-action compositions for use in the treatment of nail disease and/or for promoting nail growth
EP3603650A1 (fr) 2018-08-01 2020-02-05 Edix O Sarl Compositions injectables et a duree d'action prolongee pour leur utilisation dans le traitement de maladies de l'ongle et/ou pour accelerer la croissance de l'ongle
CN113208937A (zh) * 2020-01-21 2021-08-06 中国医学科学院北京协和医院 一种角质软化组合物及其制备方法和应用及治疗灰指甲的外用复方及其制备方法和应用
JP7664026B2 (ja) * 2020-08-06 2025-04-17 沢井製薬株式会社 エフィナコナゾール含有爪外用液
CN113234028B (zh) * 2021-04-29 2022-08-26 上海大学 一种5-氟尿嘧啶与肌氨酸的共晶体及其制备方法与用途
CN113786382B (zh) * 2021-11-04 2024-05-28 浙江得恩德制药股份有限公司 一种盐酸特比萘芬凝胶及制备方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7713618L (sv) 1977-12-01 1979-06-02 Astra Laekemedel Ab Lokalanestetisk blandning
IT1180295B (it) 1984-10-08 1987-09-23 Durst Phototechnik Srl Ingranditore o riproduttore fotografico a colori
FR2673537B1 (fr) 1991-03-08 1993-06-11 Oreal Utilisation d'agents de penetration hydrophiles dans les compositions dermatologiques pour le traitement des onychomycoses, et compositions correspondantes.
ATE221770T1 (de) 1997-05-14 2002-08-15 Galen Chemicals Ltd Topische mittel
CA2325553A1 (en) * 1998-04-17 1999-10-28 Penederm Inc. Topical formulations for the treatment of nail fungal diseases
US6368618B1 (en) 1999-07-01 2002-04-09 The University Of Georgia Research Foundation, Inc. Composition and method for enhanced transdermal absorption of nonsteroidal anti-inflammatory drugs
DE10035991A1 (de) * 2000-07-24 2002-02-14 Polichem Sa Nagellackzusammensetzung
KR100757611B1 (ko) 2001-09-04 2007-09-10 트롬스도르프 게엠베하 운트 코. 카게 알츠나이미텔 손발톱 성장의 기능장애와 질환을 치료하기 위한 플라스터
US20030091666A1 (en) * 2001-11-14 2003-05-15 Howard Murad Methods and compositions for treating dermatological disorders with Morinda citrifolia
US7138394B2 (en) 2002-09-27 2006-11-21 Alpharx Inc. Vehicle for topical delivery of anti-inflammatory compounds
DK2106805T3 (da) 2003-03-21 2011-08-15 Nexmed Holdings Inc Antifungal neglelak og anvendelsesmetode
BRPI0412975A (pt) 2003-08-25 2006-10-03 Foamix Ltd espuma penetrante para uso farmacêutico
US20060078580A1 (en) * 2004-10-08 2006-04-13 Mediquest Therapeutics, Inc. Organo-gel formulations for therapeutic applications
US20060078599A1 (en) 2004-10-12 2006-04-13 Mathew Ebmeier Pharmaceutical composition applicable to body tissue
CA2500907A1 (en) 2005-03-15 2006-09-15 Alpharx Inc. Vehicle for topical delivery of anti-inflammatory compounds
WO2006096955A1 (en) 2005-03-16 2006-09-21 Alpharx Inc. Vehicle for topical delivery of anti-inflammatory compounds
GB0511499D0 (en) * 2005-06-06 2005-07-13 Medpharm Ltd Topical ungual formulations
US20070224261A1 (en) 2006-03-22 2007-09-27 Peter Draper Eutectic liquid drug formulation
CA2653782A1 (en) 2006-06-14 2007-12-21 Dr. Reddy's Laboratories Limited Topical compositions
WO2008121709A1 (en) * 2007-03-30 2008-10-09 Transport Pharmaceuticals, Inc. Pharmaceutical formulations for iontophoretic delivery of an anti-fungal drug
AU2009275230A1 (en) * 2008-07-23 2010-01-28 Targeted Delivery Technologies Limited Methods of administering topical antifungal formulations for the treatment of fungal infections
WO2011014850A2 (en) * 2009-07-31 2011-02-03 Nuvo Research Inc. Topical eutectic-based formulations

Also Published As

Publication number Publication date
WO2011079234A2 (en) 2011-06-30
US9084754B2 (en) 2015-07-21
AU2010336441A1 (en) 2012-08-02
EP2544659A2 (en) 2013-01-16
WO2011079234A3 (en) 2011-08-18
JP2013515742A (ja) 2013-05-09
CA2785643A1 (en) 2011-06-30
US20120309843A1 (en) 2012-12-06
CN102770123A (zh) 2012-11-07
AU2010336441B2 (en) 2015-02-05

Similar Documents

Publication Publication Date Title
JP5829217B2 (ja) 高浸透性テルビナフィン製剤
Zhai et al. Advances in lipid-based colloid systems as drug carrier for topic delivery
CN102711835B (zh) 局部布洛芬制剂
US20180360757A1 (en) Biphasix cannabinoid delivery
US9415108B2 (en) Compositions for transdermal delivery of active agents
WO2011014850A2 (en) Topical eutectic-based formulations
EP2544662B1 (en) Foamable formulation
CN103429247A (zh) 勃起功能障碍和其它适应症的治疗
JP2016033168A (ja) Ｃｏｘ−２阻害剤および関連化合物、ならびにそれらを送達するためのシステムおよび方法
US20150342871A1 (en) Highly permeating terbinafine formulation
Salau et al. Enhancement of transdermal permeation of cannabinoids and their pharmacodynamic evaluation in rats
EP2498819A2 (en) Topical etoricoxib formulation comprsing an eutectic mixture of permeation enhancers
CN103442723A (zh) 治疗变态反应和其它适应症的系统和方法
JP5832302B2 (ja) ケラチンへの局所薬剤デリバリーにおける表面活性タンパク質の組成物、使用及び使用方法
ES2402921T3 (es) Composiciones químicamente estables de 4-hidroxi-tamoxifeno y sus aplicaciones terapéuticas
WO2011149645A1 (en) Topical etoricoxib formulation
Dey et al. Lipid nanoparticles for topical application of drugs for skin diseases
Priyanka et al. Use of novel penetration enhancers and techniques in tdds
WO2024175915A1 (en) Compositions for topical administration
JP6016085B2 (ja) 抗真菌外用組成物及び抗真菌外用組成物の適用方法
KR20220156309A (ko) 피부 탄력 증진 또는 피부 주름 개선용 조성물
KR20220166067A (ko) 피부 미백용 조성물
CA3083274A1 (en) Systems and methods for topical creams for warming
FR2971943A1 (fr) Compositions pharmaceutiques a action locale administrables par application cutanee

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131218

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20131218

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20141224

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150324

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150424

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150929

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20151021

R150 Certificate of patent or registration of utility model

Ref document number: 5829217

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees